GlassScriptPhysician profile
Depak Soni
NPI 1366444697
$11,455.79
in general payments reported to CMS, 2019-2025
48 companies · $2,621 in 2025
The $2,621 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,706 · 2020: $381 · 2021: $1,376 · 2022: $1,882 · 2023: $2,077 · 2024: $1,413 · 2025: $2,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,746 · Consulting Fee: $200 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,745.98 |
| Consulting Fee | $200.00 |
| Education | $164.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,359.69 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,581.14 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $886.04 | 2019-2025 | Dupixent |
| Genzyme Corporation | $725.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $617.20 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $501.89 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $449.68 | 2019-2024 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $441.01 | 2023-2025 | Lumryz |
| Amgen INC. | $351.26 | 2021-2025 | Tezspire |
| Baxter Healthcare | $269.88 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
| Harmony Biosciences LLC | $260.43 | 2020-2025 | |
| Electromed, INC. | $228.22 | 2019-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $226.17 | 2019-2025 | Zerbaxa |
| Grifols USA, LLC | $224.14 | 2019-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $223.20 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Depak Soni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.